CVS Health is moving into the biosimilar drugs market with the creation of Cordavis, a subsidiary expected to work with biosimilar manufacturers in the US. CVS will begin selling Novartis’ biosimilar to Humira, called Hyrimoz, at 80% less than Humira’s current $7,000 per month price tag in 2024. CVS is the last of the big three US pharmaceutical benefit managers to publicly support Humira biosimilars.
Granular Policy Enforcement for Hybrid Classical-Quantum AI Workflows
Master granular policy enforcement for hybrid classical-quantum AI workflows. Secure your MCP servers with post-quantum encryption and advanced threat detection. The post Granular Policy Enforcement
